title: Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC).
abstract: The antitumoral activity and toxicity of a new daunorubicin analog (4-demethoxydaunorubicin, IMI 30, Idarubicin) was tested in 20 consecutive patients with non-small cell lung cancer mostly pretreated with chemotherapy. The drug was administered orally at a dose of 15 mg/m2 for three days every 3-4 weeks. There were no clinical responses. Hematological and nonhematological toxicities were mild.
authors.affiliation: Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Ardizzoni
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.forename: L
authors.initials: L
authors.lastname: Repetto
authors.forename: M
authors.initials: M
authors.lastname: De Palma
authors.forename: L
authors.initials: L
authors.lastname: Canobbio
authors.forename: M
authors.initials: M
authors.lastname: Gulisano
authors.forename: V
authors.initials: V
authors.lastname: Fusco
authors.forename: R
authors.initials: R
authors.lastname: Rosso
authors.forename: F
authors.initials: F
authors.lastname: Ganzina
mesh_terms: D000284:Administration, Oral; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D015255:Idarubicin